Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX:NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.
The results do not reflect contributions from the acquisition of Novamind, completed after quarter end, on June 10. On the purchase, founder & CEO Payton Nyquvest said: "Now, with 13 wellness clinics across North America, four clinical research sites and a dedicated psychedelics research facility, Numinus is firmly positioned as a leading mental health care company providing psychedelic-assisted therapies. We're very pleased with how our operations are integrating and with the collaborative efforts we are already seeing across our new expanded team."
